ストックスクリーナーアプリを入手
5.10
3.24%
0.16
前日終値:
$4.94
開ける：
$5.05
24時間の取引高:
891.61K
Relative Volume:
1.57
時価総額：
$537.96M
収益：
$45.44M
当期純損益:
$-35.43M
株価収益率:
-15.00
EPS:
-0.34
ネットキャッシュフロー:
$-25.39M
1週間 パフォーマンス:
+9.91%
1か月 パフォーマンス:
+20.28%
6か月 パフォーマンス:
+15.91%
1年 パフォーマンス:
-0.39%
1日の値動き範囲:
$4.95
$5.20
1週間の範囲:
$4.64
$5.20
52週間の値動き範囲:
$3.165
$5.3166
Maxcyte Inc Stock (MXCT) Company Profile
MXCT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
5.10 | 537.96M | 45.44M | -35.43M | -25.39M | -0.34 |
|
ABT
Abbott Laboratories
|
116.79 | 201.01B | 41.22B | 5.77B | 6.49B | 3.29 |
|
SYK
Stryker Corp
|
395.85 | 150.90B | 21.97B | 3.59B | 3.21B | 9.33 |
|
BSX
Boston Scientific Corp
|
100.91 | 148.72B | 15.91B | 1.79B | 1.89B | 1.21 |
|
MDT
Medtronic Plc
|
88.38 | 113.33B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
69.97 | 41.27B | 6.60B | 4.16B | 490.10M | 6.93 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-11-29 | 開始されました | Craig Hallum | Buy |
| 2021-10-15 | 再開されました | Cowen | Outperform |
| 2021-08-24 | 開始されました | BTIG Research | Buy |
| 2021-08-24 | 開始されました | Cowen | Outperform |
| 2021-08-24 | 開始されました | Stephens | Overweight |
| 2021-08-24 | 開始されました | Stifel | Buy |
| 2021-08-24 | 開始されました | Wedbush | Outperform |
| 2021-08-24 | 開始されました | William Blair | Outperform |
すべてを表示
Maxcyte Inc (MXCT) 最新ニュース
BlackRock Increases Stake in MaxCyte to 7.57% - TipRanks
MaxCyte (NASDAQ: MXCT) Announces Preliminary Financial Results for Q4 and FY 2024ROCKVILLE, MD, January 13, 2025 — MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a prominent cell-engineering company specializing in platform technologies for adv - Defense World
MaxCyte Announces Change in Major Holdings by BlackRock - TipRanks
MaxCyte, Inc. (NASDAQ:MXCT) Stake Boosted by Barclays PLC - Defense World
Barclays PLC Has $645,000 Position in MaxCyte, Inc. (NASDAQ:MXCT) - MarketBeat
All You Need to Know About MaxCyte (MXCT) Rating Upgrade to Strong Buy - MSN
BlackRock Increases Stake in MaxCyte, Inc. - TipRanks
What Is MaxCyte, Inc.'s (LON:MXCT) Share Price Doing? - Yahoo Finance
Maxcyte general counsel sells shares worth $20,271 By Investing.com - Investing.com Nigeria
MaxCyte estimates higher Q4 core revenue from last year - MSN
David I. Sandoval Sells 4,466 Shares of MaxCyte, Inc. (NASDAQ:MXCT) Stock - MarketBeat
Maxcyte general counsel sells shares worth $20,271 - Investing.com
MaxCyte expects growth in core revenue for Q4 and full year 2024 - Investing.com Canada
MaxCyte (NASDAQ:MXCT) Shares Up 8.2%Here's Why - MarketBeat
MaxCyte expects growth in core revenue for Q4 and full year 2024 By Investing.com - Investing.com South Africa
MaxCyte flags full-year revenue at top end of expectations - ShareCast
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
MaxCyte Reports 2024 Financial Growth and Industry Milestones - TipRanks
MaxCyte Q4 Revenue Grows 16%, Adds Six Strategic Partners Amid Cell Therapy Milestone - StockTitan
Jane Street Group LLC Has $260,000 Stock Position in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte Announces Leadership Transition and Strategic Focus - MSN
MaxCyte Expands Common Stock Issuance to 105.7 Million Shares - TipRanks
Franklin Resources Inc. Makes New Investment in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
Geode Capital Management LLC Grows Holdings in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
Barclays PLC Grows Stock Holdings in MaxCyte, Inc. (NASDAQ:MXCT) - MarketBeat
Barclays PLC Grows Holdings in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte director sells shares after option exercise By Investing.com - Investing.com South Africa
Art Mandell Retires from MaxCyte Board - citybiz
MaxCyte director sells shares after option exercise - Investing.com India
Maxcyte director Johnston sells shares worth $12,020 - Investing.com India
MaxCyte Director Exercises Stock Options and Executes Sales - TipRanks
Maxcyte director Johnston sells shares worth $12,020 By Investing.com - Investing.com Australia
MaxCyte, Inc. (NASDAQ:MXCT) Director Sells $12,030.00 in Stock - MarketBeat
State Street Corp Grows Stake in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte Streamlines Workforce and Boosts Revenue Outlook - MSN
MaxCyte board member Art Mandell retires By Investing.com - Investing.com Australia
MaxCyte, Inc. Announces Retirement of Board Member Art Mandell - Marketscreener.com
MaxCyte board member Art Mandell retires - Investing.com India
MaxCyte Announces Retirement of Board Member Art Mandell - The Manila Times
MaxCyte Announces Board Member Retirement - TipRanks
MaxCyte Board Member Art Mandell to Exit After 18-Year Tenure Marked by Landmark CRISPR Achievements - StockTitan
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 27,111 Shares of MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte Announces Change in Shareholder Voting Rights Due to BlackRock Holdings - TipRanks
Maxcyte Inc (MXCT) 財務データ
収益
当期純利益
現金流量
EPS
Maxcyte Inc (MXCT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Johnston John Joseph | Director |
Dec 26 '24 |
Option Exercise |
2.93 |
3,000 |
8,796 |
144,950 |
| Johnston John Joseph | Director |
Dec 26 '24 |
Sale |
4.01 |
3,000 |
12,021 |
141,950 |
3.55%
大文字化:
|
ボリューム (24 時間):